Case Report (n=1)
Molecular techniques like FISH are crucial for diagnosing rare uterine Ewing's sarcoma/pPNET, and multimodal therapy may improve patient outcomes.
Answers are grounded in this paper and cite their sources.
Multimodal therapy merits consideration in rare uterine Ewing sarcoma; leaves open optimal protocols pending larger studies.
Ewing's sarcoma/peripheral primitive neuroectodermal tumors (ES/pPNET) are a group of small round cell sarcomas that show varying degrees of neuroectodermal differentiation characterized by translocation involving the EWS gene. Uterine ES/pPNET is a rare entity. A 29-year-old Chinese female who presented with abdominal swelling and pain was diagnosed with a primary uterine ES/pPNET on the basis of clinicopathologic, immunohistochemical and fluorescence in situ hybridization (FISH) data. She was given a multimodal treatment, including neoadjuvant, 95% cytoreductive, chemotherapy and radiotherapy. The patient is currently alive with persistent disease after 18 months of follow-up. We emphasized the crucial role of molecular techniques in the differential diagnosis of small round cell tumors in this unusual location. Multimodal therapy may improve the outcomes of patients.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2014) conducted a case report in Uterine Ewing's sarcoma/peripheral primitive neuroectodermal tumors (ES/pPNET) (n=1). Multimodal treatment (neoadjuvant chemotherapy, cytoreductive surgery, and radiotherapy) was evaluated on Patient survival and disease status.
Synapse has enriched 10 related papers. Consider them for comparative context: